

## **The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB**

**The Nomination Committee of SynAct Pharma AB (“SynAct”) has informed the company that the Nomination Committee proposes that Kerstin Hasselgren is elected as a new ordinary board member of SynAct for the period until the end of the next Annual General Meeting, together with the board members elected at the Annual General Meeting on 21 May 2021.**

Kerstin Hasselgren (born 1961) is currently CFO of Xspray Pharma AB listed on Nasdaq Stockholm. Kerstin Hasselgren has extensive experience from working in large public international companies such as VP Corporate Business Control at SSAB, CFO at Alstom Transport Nordic, VP Finance Global Operations at AstraZeneca and VP Finance Global R&D at AstraZeneca. Kerstin Hasselgren has a degree of Master of Science in Business and Economics from the Stockholm School of Economics.

The proposal to elect Kerstin Hasselgren as new board member will be handled at an Extraordinary General Meeting to be held on March 28, 2022.

Provided that Kerstin Hasselgren is elected as a new board member, the board intends to appoint Kerstin Hasselgren as chairman of the audit committee.

"With her experience from the pharmaceutical industry and not least from listing Xspray Pharma on the Nasdaq Main Market, Kerstin Hasselgren will be an extremely important reinforcement for our board," says Torbjørn Bjerke, chairman of SynAct.

For more information, please refer to the notice convening the Extraordinary General Meeting, which will be published as a separate press release.

*The information was submitted, through the agency of the contact person below, for publication on March 9, 2022 at 07:55 a.m.*

### **For further information about SynAct Pharma AB, please contact:**

#### **Jeppe Øvlesen**

CEO, SynAct Pharma AB

Phone: +45 28 44 75 67

Mail: [joo@synactpharma.com](mailto:joo@synactpharma.com)

#### **Thomas Jonassen**

CSO, SynAct Pharma AB

Phone: +45 40 15 66 69

Mail: [tj@synactpharma.com](mailto:tj@synactpharma.com)

### **About SynAct Pharma AB**

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute

deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: [www.synactpharma.com](http://www.synactpharma.com).